Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Multiple myeloma is a cancer of the plasma cells in which abnormal plasma cells multiply uncontrollably in the bone marrow and occasionally in other parts of the body. It is the second most common ...

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...

Multiple myeloma is a rare blood cancer that is not hereditary. However, a family history of the disease may increase your risk of developing it.

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

M ultiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...

This is the overall classification for multiple myeloma and abnormal growth of malignant plasma cells. C90.0. This is the overall classification for multiple myeloma. Within this code, you might be: ...